BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24567546)

  • 1. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.
    Oda M; Koyanagi S; Tsurudome Y; Kanemitsu T; Matsunaga N; Ohdo S
    Mol Pharmacol; 2014 May; 85(5):715-22. PubMed ID: 24567546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
    Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
    J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
    Tanihara Y; Masuda S; Katsura T; Inui K
    Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
    Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
    Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
    Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.
    Nakamura T; Yonezawa A; Hashimoto S; Katsura T; Inui K
    Biochem Pharmacol; 2010 Dec; 80(11):1762-7. PubMed ID: 20813096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
    Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
    Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platinum agent-induced nephrotoxicity via organic cation transport system].
    Yonezawa A
    Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
    Filipski KK; Mathijssen RH; Mikkelsen TS; Schinkel AH; Sparreboom A
    Clin Pharmacol Ther; 2009 Oct; 86(4):396-402. PubMed ID: 19625999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
    Yokoo S; Yonezawa A; Masuda S; Fukatsu A; Katsura T; Inui K
    Biochem Pharmacol; 2007 Aug; 74(3):477-87. PubMed ID: 17582384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
    Guo D; Yang H; Li Q; Bae HJ; Obianom O; Zeng S; Su T; Polli JE; Shu Y
    Pharm Res; 2018 Sep; 35(11):204. PubMed ID: 30191328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters.
    Saito Y; Okamoto K; Kobayashi M; Narumi K; Yamada T; Iseki K
    Eur J Pharmacol; 2017 Sep; 811():191-198. PubMed ID: 28529140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging increases the susceptibility of cisplatin-induced nephrotoxicity.
    Wen J; Zeng M; Shu Y; Guo D; Sun Y; Guo Z; Wang Y; Liu Z; Zhou H; Zhang W
    Age (Dordr); 2015 Dec; 37(6):112. PubMed ID: 26534724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of cepharanthin on cisplatin-induced renal toxicity through metallothionein expression.
    Sogawa N; Hirai K; Sogawa C; Ohyama K; Miyazaki I; Tsukamoto G; Asanuma M; Sasaki A; Kitayama S
    Life Sci; 2013 Apr; 92(12):727-32. PubMed ID: 23399700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats.
    González R; Romay C; Borrego A; Hernández F; Merino N; Zamora Z; Rojas E
    Mediators Inflamm; 2005 Aug; 2005(3):139-43. PubMed ID: 16106099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
    Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
    Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2.
    Wang G; Bi Y; Xiong H; Bo T; Han L; Zhou L; Zhang C; Zhang Y
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S447-S459. PubMed ID: 34592875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
    Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
    Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.